Last €43.12 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 11:50 AM 11/3/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ELI LILLY & CO (LLY) in the last 6 months

Announced 10/27/14
Eli Lilly and Company, United States Veterinary Products
Merger/Acquisition

Virbac SA (ENXTPA:VIRP) entered into an agreement to acquire United States Veterinary products from Eli Lilly and Company (NYSE:LLY) on October 27, 2014. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two major parasiticides, Sentinel®Flavor Tabs and Sentinel® Spectrum. The transaction is subject to ...
Read More


LLY's price was unchanged after the transaction was announced on 10/27/14.
Investor / Buyer
Virbac SA
Creditor / Lender
Eli Lilly and Company
 
Announced 07/29/14
51.00M for Accelerator IV
Fund Raising

Accelerator IV held its first close at $51.1 million on July 29, 2014. Investors in the fund include Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corporation, The Partnership Fund for New York City, WRF Capital, Pfizer Venture Investments, Alexandria Venture Investments, and Arch Venture Partners.


LLY's price was unchanged after the transaction was announced on 07/29/14.
Investor / Buyer
Alexandria Venture Investments
Arch Venture Partners, L.P.
Eli Lilly and Company
Harris & Harris Group, Inc.
Johnson & Johnson Development Corporation
New York City Investment Fund Manager, Inc.
Pfizer Venture Investments
WRF Capital
 
Announced 07/14/14
Eli Lilly and Co., Sollpura
Merger/Acquisition

Alkira Therapeutics, Inc. acquired Sollpura from Eli Lilly and Company (NYSE:LLY) on July 11, 2014. It is intended that Alkira will make all future contingent milestone payments under the license agreement upon product approval and on certain annual sales achievements and will make royalty payments on any product sales after achieving certain sales thresholds of cumulative net sales of Sollpura.


LLY's price was unchanged after the transaction was announced on 07/14/14.
Investor / Buyer
Alkira Therapeutics, Inc.
Creditor / Lender
Eli Lilly and Company
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €43.12 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.50 USD -0.3455
AbbVie Inc $66.99 USD +0.0125
AstraZeneca PLC 4,539 GBp -17.00
Novo Nordisk A/S kr264.50 DKK +3.70
Teva Pharmaceutical Industries Ltd $57.29 USD +0.11
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 28.2x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 29.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.